¼¼°èÀÇ Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV) ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå
Human Immunodeficiency Virus (HIV) Rapid Test Kits
»óǰÄÚµå : 1792937
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 366 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV) ½Å¼Ó °Ë»ç ŰƮ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 12¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 8¾ï 1,430¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV) ½Å¼Ó °Ë»ç ŰƮ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 6.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 12¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ HIV ½Å¼Ó ¸é¿ªÃøÁ¤ °Ë»ç´Â CAGR 7.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 8¾ï 4,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. HIV ½Å¼Ó ºÐÀÚÁø´Ü °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 2,180¸¸ ´Þ·¯, Áß±¹Àº CAGR 9.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV) ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀº 2024³â¿¡ 2¾ï 2,180¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 9.9%¸¦ ´õµë¾î, 2030³â±îÁö 2¾ï 4,040¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.0%¿Í 6.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV) ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°øÁߺ¸°Ç ¿ì¼±¼øÀ§ÀÇ º¯È­´Â HIV ½Å¼Ó °Ë»ç ŰƮ ¼ö¿ä¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

HIV ½Å¼Ó °Ë»ç ŰƮÀÇ ¼¼°è ¼ö¿ä´Â Á¶±â Áø´Ü, ¿¹¹æ ÀÇ·á, ÀÇ·á Á¢±Ù¼º È®´ë¸¦ À§ÇÑ °øÁß º¸°Ç Àü·«ÀÇ ÁøÈ­¿¡ µû¶ó Á¡Á¡ ´õ ¸¹Àº ¼ö¿ä¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. °¢±¹ÀÌ °øÁߺ¸°Ç À§ÇùÀ¸·Î¼­ HIV¸¦ Á¦°ÅÇÑ´Ù´Â ¾ß½ÉÂù ¸ñÇ¥¸¦ ÇâÇØ ³ª¾Æ°¡°í ÀÖ´Â °¡¿îµ¥, Àû½Ã¿¡ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â °Ë»ç´Â °³ÀÔ¿¡ ÀÖ¾î °¡Àå Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. Ç÷¾×À̳ª °æ±¸ »ùÇÃÀ» ÅëÇØ ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â ½Å¼Ó °Ë»ç ŰƮ´Â ±âÁ¸ °Ë»ç½Ç¿¡¼­ °Ë»çÇÒ ¼ö ¾ø¾ú´ø »ç¶÷µé¿¡°Ô °Ë»ç °á°ú¸¦ Á¦°øÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì À¯¿ëÇÏ°Ô È°¿ëµÇ°í ÀÖ½À´Ï´Ù. Áö¿ª ±â¹Ý °Ë»ç ÀÌ´Ï¼ÅÆ¼ºê, À̵¿ Áø·á¼Ò, ¿Üµý Áö¿ªÀ̳ª ¼Ò¿ÜµÈ Áö¿ª¿¡¼­ÀÇ ¾Æ¿ô¸®Ä¡ ÇÁ·Î±×·¥Àº ÀÌ Å°Æ®¸¦ HIV °ËÁø¿¡ ÇʼöÀûÀÎ µµ±¸·Î ¹Þ¾ÆµéÀ̰í ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç±â°üµµ ÀÚ°¡Áø´Ü ŰƮ¸¦ ¿ì¼±ÀûÀ¸·Î »ç¿ëÇÔÀ¸·Î½á, °³ÀÎÀûÀ¸·Î ÆíÇÑ ½Ã°£¿¡ °Ë»ç¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï Àå·ÁÇϰí, Áø·á¼Ò ¹æ¹®¿¡ ´ëÇÑ Æí°ß°ú µÎ·Á¿òÀ» ÁÙ¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ Å°Æ®´Â ³²¼º°ú ¼º°ü°è¸¦ °¡Áø ³²¼º, ¼º³ëµ¿ÀÚ, Á¤¸ÆÁÖ»ç ¾à¹° »ç¿ëÀÚ, À¯º´·üÀÌ ³ôÀº Áö¿ª ÁֹΠµî °íÀ§Ç豺¿¡°Ô ƯÈ÷ È¿°úÀûÀÔ´Ï´Ù. ³ëÃâ Àü ¿¹¹æ¾à(PrEP)°ú °°Àº ¿¹¹æ ÇÁ·Î±×·¥ ¹× ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÇ µîÀåÀº Á¤±âÀûÀÎ HIV °Ë»ç°¡ »çÈÄ Á¶Ä¡°¡ ¾Æ´Ñ ±Ô¹üÀÌ µÉ ¼ö ÀÖ´Â º¸´Ù Àû±ØÀûÀÎ Á¢±Ù ¹æ½Ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »óȲ¿¡¼­ ½Å¼Ó °Ë»ç ŰƮ´Â Á¶±â Áø´Ü»Ó¸¸ ¾Æ´Ï¶ó Ä¡·á ¿¬°è±îÁö Áö¿øÇÏ¿© °¨¿°ºÎÅÍ °³ÀÔ±îÁöÀÇ ±â°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç Á¤Ã¥ÀÌ ºÀ¼â¿¡¼­ ¿¹¹æ°ú ±ÇÇÑ ºÎ¿©·Î ÀüȯµÇ°í ÀÖ´Â °¡¿îµ¥, HIV ½Å¼Ó °Ë»ç ŰƮ´Â Áö¿ª Â÷¿øÀÇ ÀÇ·á ¹× Áúº´ °ü¸®ÀÇ ÇÙ½ÉÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

°Ë»ç ±â¼úÀÇ Çõ½ÅÀÌ ½Å¼Ó ŰƮ¸¦ ´õ È¿°úÀûÀÌ°í ½±°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î HIV ½Å¼Ó °Ë»ç ŰƮÀÇ À¯È¿¼º, »ç¿ë ÆíÀǼº, Ȱ¿ë ¹üÀ§°¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. Â÷¼¼´ë ½Å¼Ó °Ë»ç´Â ¹Î°¨µµ¿Í ƯÀ̵µ°¡ ½ÇÇè½Ç ±â¹Ý °Ë»ç¿¡ ÇÊÀûÇÒ Á¤µµ·Î ¹Î°¨µµ¿Í ƯÀ̵µ°¡ Çâ»óµÇ¾î ´õ ºü¸¦ »Ó¸¸ ¾Æ´Ï¶ó ´õ Á¤È®ÇØÁ³½À´Ï´Ù. °³¹ß¾÷ü´Â HIV-1 Ç×ü¿Í HIV-2 Ç×ü, ±×¸®°í p24¿Í °°Àº Ç׿øÀ» °ËÃâÇÒ ¼ö Àִ ŰƮ¸¦ °³¹ßÇÏ¿© ³ëÃâ ÈÄ Á¶±â ¹ß°ßÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¼Õ°¡¶ôÀ» Â´Â Ç÷¾×À̳ª ±¸°­ ¸éºÀ°ú °°Àº »ùÇà äÃë ¹æ¹ýÀÇ Çõ½ÅÀ¸·Î °Ë»ç °úÁ¤ÀÌ ´ú ħ½ÀÀûÀ̾ ´Ù¾çÇÑ »ç¿ëÀÚÃþÀÌ ¹Þ¾ÆµéÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ãø¸é È帧 ÀåÄ¡¿Í ÄÄÆÑÆ® Ä«¼¼Æ®¸¦ Æ÷ÇÔÇÑ »ç¿ëÀÚ Ä£È­ÀûÀÎ Æ÷¸ËÀº Àü¹®ÀûÀÎ ±³À° ¾øÀ̵µ ½±°Ô ´Ù·ê ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Æ¯Â¡À¸·Î ÀÎÇØ ÀÌ Å°Æ®´Â ÇöÀå ȯ°æ, °¡Á¤ ȯ°æ, ÀÚ¿øÀÌ Á¦ÇÑµÈ Áø·á¼Ò¿¡¼­ »ç¿ëÇϱ⿡ ÀÌ»óÀûÀÔ´Ï´Ù. ¶ÇÇÑ ÀϺΠŰƮ¿¡´Â °á°ú ÇØ¼®, °Ë»ç ÈÄ »ó´ã, ÈÄ¼Ó °ü¸® ¸®¼Ò½º¸¦ Á¦°øÇÏ´Â ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ǿ¡ ¿¬°áµÈ QRÄڵ尡 Æ÷ÇԵǾî ÀÖ¾î µðÁöÅÐ ±â´ÉÀÌ ÇÁ·Î¼¼½º¿¡ ÅëÇյǾî ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷ü´Â ¶ÇÇÑ º¸°ü ±â°£, º¸°ü Á¶°Ç, È޴뼺À» °³¼±ÇÏ¿© ´Ù¾çÇÑ ±âÈÄ ¹× ¹°·ù Á¶°Ç¿¡¼­µµ ŰƮ¸¦ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ¼ÒÇüÈ­, ´Ü¼øÈ­, µðÁöÅÐÈ­ÀÇ °áÇÕÀ¸·Î Ç÷¾ÐÀ̳ª Ç÷´ç ¼öÄ¡ È®Àΰú °°Àº °Ë»ç°¡ ÀÏ»óÀûÀÎ °Ç°­ ½À°üÀ¸·Î ÀÚ¸® ÀâÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±â¼úÀÌ ÇöÀå Áø´ÜÀÇ ÇѰ踦 °è¼Ó ³ÐÇô°¡°í ÀÖ´Â °¡¿îµ¥, HIV ½Å¼Ó °Ë»ç ŰƮ´Â ´õ Á¤È®Çϰí, ´õ Àú·ÅÇϸç, º¸ÆíÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÉ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

Á¤Ã¥ ÇÁ·¹ÀÓ¿öÅ©¿Í ¼¼°èº¸°ÇÇÁ·Î±×·¥Àº ¾î¶»°Ô ½ÃÀå È®´ë¸¦ Áö¿øÇϰí Àִ°¡?

HIV ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀÇ ¼ºÀåÀº ÁöÁöÀûÀÎ Á¤Ã¥ ÇÁ·¹ÀÓ¿öÅ©¿Í °Ë»ç ¹× Ä¡·á º¸±ÞÀ» À§ÇÑ ±¹Á¦ º¸°Ç±â±¸ÀÇ ³ë·Â°ú ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÇ¾î ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO), À¯¿£¿¡ÀÌÁî(UNAIDS), Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC) µîÀÇ ±â°üÀº °¨¿°·ü °¨¼Ò¿Í Á¶±â Ä¡·á ¼º°ú ´Þ¼ºÀ» À§ÇÑ ¹æ¾ÈÀ¸·Î HIV °Ë»ç È®´ë¸¦ Áö¼ÓÀûÀ¸·Î ÁÖÀåÇØ¿Ô½À´Ï´Ù. ¸¹Àº ±¹°¡µéÀÌ ±¹Á¦ ±Ç°í¿¡ µû¶ó ±¹°¡ HIV/AIDS Àü·«À» Á¶Á¤Çϰí, °øÁߺ¸°Ç Ä·ÆäÀο¡ ½Å¼Ó °Ë»ç¸¦ µµÀÔÇϰí, ÀÚ°¡ Áø´Ü ŰƮ¸¦ ½ÃÁß ¶Ç´Â Åë½ÅÆÇ¸Å¸¦ ÅëÇØ ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. °ø°ø Áø·á¼Ò, ºñ¿µ¸® ´Üü, ±âºÎÀÚ Áö¿ø ÇÁ·Î±×·¥À» ÅëÇØ º¸Á¶±ÝÀ» Áö¿øÇÔÀ¸·Î½á, ÀÌ Å°Æ®´Â ´Ù¸¥ ¹æ¹ýÀ¸·Î´Â °Ë»ç ¼­ºñ½º¸¦ ¹ÞÀ» ¼ö ¾ø´Â Àú¼ÒµæÃþµµ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. HIV °¨¿°ÀÚ°¡ ¸¹Àº Áö¿ª¿¡¼­´Â Áö¼ÓÀûÀÎ °ø±Þ°ú °Ë»ç »ç¿ë¿¡ ´ëÇÑ ±³À°À» º¸ÀåÇϱâ À§ÇØ ¾çÀÚ °£ ÆÄÆ®³Ê½Ê, °³¹ß º¸Á¶±Ý, Á¦¾à»ç¿ÍÀÇ Çù·ÂÀ» ÅëÇØ °Ë»ç ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áö¿øÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±³À° Ä·ÆäÀÎÀº ƯÈ÷ ¼ºÀûÀ¸·Î Ȱµ¿ÀûÀÎ »ç¶÷µé¿¡ ´ëÇÑ Á¤±âÀûÀÎ °Ë»çÀÇ Á߿伺À» °­Á¶Çϰí ÀÖÀ¸¸ç, ±× °á°ú ½Ã¹ÎµéÀº ½Å¼ÓŰƮ »ç¿ë¿¡ ´ëÇÑ ÀÇÁö°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ±â°üÀº ±â¼ú Çõ½Å°ú ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϱâ À§ÇØ »õ·Î¿î ŰƮÀÇ ½ÂÀÎ °æ·Î¸¦ °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϺΠÁ¤ºÎ´Â Àú·ÅÇÑ °¡°ÝÀ¸·Î ³Î¸® º¸±ÞÇϱâ À§ÇØ ±¹°¡ Á¶´Þ Á¦µµ³ª ´ë·® ±¸¸Å °è¾àÀ» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥ ÁÖµµÀÇ ³ë·ÂÀº Á¢±ÙÀÇ À庮À» Á¦°ÅÇÒ »Ó¸¸ ¾Æ´Ï¶ó »çÈİü¸®, Ä¡·á ¿¬°è, ¸ð´ÏÅ͸µÀ» À§ÇÑ ÀÎÇÁ¶ó¸¦ °­È­ÇÏ´Â µ¥¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂµéÀÌ °áÇÕµÇ¾î ½Å¼ÓÇÑ HIV °Ë»ç°¡ Á¤±ÔÈ­µÇ°í Àü ¼¼°è Áö¿ª»çȸ¿¡¼­ È®´ëµÉ ¼ö ÀÖ´Â Áö¿øÀûÀÎ »ýŰ谡 ±¸ÃàµÇ°í ÀÖ½À´Ï´Ù.

¼¼°è HIV ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

HIV ½Å¼Ó °Ë»ç ŰƮ ½ÃÀåÀÇ ¼ºÀåÀº ¿ªÇÐÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¿äÀεéÀº Á¢±Ù °¡´ÉÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä¸¦ Á¾ÇÕÀûÀ¸·Î ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä«, ¾Æ½Ã¾Æ ÀϺΠÁö¿ª, ¼±Áø±¹ÀÇ ¼Ò¿ÜµÈ Áö¿ª»çȸ¿¡¼­ HIVÀÇ ¼¼°èÀû À¯ÇàÀÌ Áö¼ÓµÇ¸é¼­ ±¤¹üÀ§ÇÑ °Ë»ç ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áö¼ÓÀûÀÎ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. HIV¿Í ¼ºº´¿¡ ´ëÇÑ ÀϹÝÀεéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­, ƯÈ÷ ÀþÀº Ãþ°ú ¿©·¯ ÆÄÆ®³Ê¸¦ °¡Áø »ç¶÷µé »çÀÌ¿¡¼­ Á¤±âÀûÀÎ °Ë»ç¸¦ ¹ÞÀ¸·Á´Â »ç¶÷µéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¿ø°ÝÀÇ·á¿Í e-Çコ Ç÷§ÆûÀÇ È®´ë´Â ÀÚ°¡Áø´Ü ŰƮÀÇ º¸±Þ°ú Ȱ¿ëÀ» ÃËÁøÇÏ°í ½ÃÀå ¹üÀ§¸¦ ´õ¿í ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ½Å¼Ó °Ë»ç ŰƮ´Â °¡°ÝÀÌ Àú·ÅÇÏ°í °£ÆíÇϱ⠶§¹®¿¡ ±âÁ¸ °Ë»ç½Ç ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ ¼ö ¾ø°Å³ª °æÁ¦ÀûÀ¸·Î Á¢±ÙÇϱ⠾î·Á¿î Àú¼Òµæ ȯ°æ¿¡¼­ ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù. °ø°ø Àå¼ÒÀÇ ÀÚµ¿ÆÇ¸Å±â, ¾à±¹ ¼ö·É ¸ðµ¨ µî ¹°·ù ¹× À¯Åë ä³ÎÀÇ Çõ½ÅÀº °Ë»ç ŰƮ¸¦ º¸´Ù ´«¿¡ Àß ¶ç°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹Í°ú °°Àº ¼¼°è ºñ»ó»çÅ´ ºÐ»êÇü ÀÚ°¡ Áø´ÜÀÇ Á߿伺À» °­Á¶Çϰí, ½Å¼Ó °Ë»ç Æ÷¸ËÀÇ ¸Å·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¹Î°£±â¾÷°ú °ø°ø±â°üÀÇ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ÅõÀÚ·Î ´Ù¾çÇÑ »ç¿ëÀÚ ´ÏÁî, ±ÔÁ¦ ȯ°æ, Áö¿ªÀû Áúº´ ÇÁ·ÎÆÄÀÏ¿¡ ´ëÀÀÇÏ´Â Á¦Ç°ÀÌ ¸¸µé¾îÁö°í ÀÖ½À´Ï´Ù. »çȸÀû ¼ö¿ë°ú ÀÇ·á ½Ã½ºÅÛ ÅëÇÕÀ̶ó´Â µÎ °¡Áö ¿äÀο¡ ÈûÀÔ¾î HIV ½Å¼Ó °Ë»ç ŰƮ´Â Æ´»õ Á¦Ç°¿¡¼­ ÇʼöÀûÀÎ °øÁß º¸°Ç µµ±¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü, Ä¡·á ¿¬°è, Àü¿°º´ ÅëÁ¦¿¡ ÀÖ¾î HIV ½Å¼Ó °Ë»ç ŰƮÀÇ ¿ªÇÒÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÒ °ÍÀ̸ç, ÇâÈÄ Åº·ÂÀûÀÌ°í ¹ÝÀÀ¼ºÀÌ ³ôÀº ½ÃÀåÀÌ Çü¼ºµÉ °ÍÀÌ È®½Ç½ÃµË´Ï´Ù.

ºÎ¹®

À¯Çü(HIV ½Å¼Ó ¸é¿ªÃøÁ¤ °Ë»ç, HIV ½Å¼Ó ºÐÀÚÁø´Ü °Ë»ç), À¯Åë ä³Î(¿ÀÇÁ¶óÀÎ À¯Åë ä³Î, ¿Â¶óÀÎ À¯Åë ä³Î), ÃÖÁ¾»ç¿ëÀÚ(Áø´Ü ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market to Reach US$1.2 Billion by 2030

The global market for Human Immunodeficiency Virus (HIV) Rapid Test Kits estimated at US$814.3 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. HIV Rapid Immunoassay Tests, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$847.7 Million by the end of the analysis period. Growth in the HIV Rapid Molecular Diagnostic Tests segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$221.8 Million While China is Forecast to Grow at 9.9% CAGR

The Human Immunodeficiency Virus (HIV) Rapid Test Kits market in the U.S. is estimated at US$221.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$240.4 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market - Key Trends & Drivers Summarized

How Are Changing Public Health Priorities Influencing the Demand for HIV Rapid Test Kits?

The global demand for HIV rapid test kits is increasingly shaped by evolving public health strategies aimed at early diagnosis, preventive care, and expanded healthcare access. As nations work toward the ambitious goal of eliminating HIV as a public health threat, timely and accessible testing has become one of the most critical components of intervention. Rapid test kits, which offer results within minutes using blood or oral samples, are proving invaluable in reaching populations that traditional laboratory testing often fails to serve. Community-based testing initiatives, mobile health units, and outreach programs in remote and underserved areas have embraced these kits as essential tools for HIV screening. Public health agencies are also prioritizing self-testing kits to encourage individuals to test privately and at their own convenience, thus reducing stigma and fear associated with clinic visits. These kits have been especially effective in reaching high-risk populations such as men who have sex with men, sex workers, intravenous drug users, and individuals in high-prevalence regions. The rise of preventive programs like pre-exposure prophylaxis (PrEP) and awareness campaigns are contributing to a more proactive approach, where regular HIV testing becomes a norm rather than a reactive measure. In this context, rapid test kits support not just early diagnosis but also linkage to treatment, reducing the period between infection and intervention. As public health policy continues to shift from containment to prevention and empowerment, HIV rapid test kits are emerging as a cornerstone of community-level healthcare and disease control.

Why Are Innovations in Testing Technology Making Rapid Kits More Effective and Accessible?

Advancements in diagnostic technology are significantly enhancing the effectiveness, usability, and reach of HIV rapid test kits. Newer generations of rapid tests are not only faster but also more accurate, with improved sensitivity and specificity that rival laboratory-based tests. Manufacturers are developing kits capable of detecting both HIV-1 and HIV-2 antibodies, as well as antigens like p24, allowing for earlier detection post-exposure. Innovations in sample collection methods, such as finger-prick blood and oral swabs, have made the testing process less invasive and more acceptable across diverse user groups. User-friendly formats, including lateral flow devices and compact cassettes, are being designed for easy handling without the need for specialized training. These features make the kits ideal for use in field settings, home environments, and resource-limited clinics. Furthermore, digital enhancements are being integrated into the process, with some kits including QR codes linked to mobile applications that provide result interpretation, post-test counseling, and follow-up care resources. Manufacturers are also focusing on improving shelf life, storage conditions, and portability, ensuring that the kits remain viable in a variety of climates and logistical conditions. The combination of miniaturization, simplification, and digitization is making it possible for testing to become an everyday health habit, much like checking blood pressure or glucose levels. As technology continues to push the boundaries of what is possible in point-of-care diagnostics, HIV rapid test kits are poised to become even more accurate, affordable, and universally accessible.

How Are Policy Frameworks and Global Health Programs Supporting Market Expansion?

The growth of the HIV rapid test kits market is closely tied to supportive policy frameworks and the commitment of global health organizations toward widespread testing and treatment accessibility. Agencies such as the World Health Organization (WHO), UNAIDS, and the Centers for Disease Control and Prevention (CDC) have consistently advocated for scaling up HIV testing as a pathway to reducing transmission rates and achieving early treatment outcomes. Many countries are aligning their national HIV/AIDS strategies with international recommendations, incorporating rapid testing into public health campaigns and making self-test kits available over the counter or via mail-order systems. Subsidized distribution through public clinics, non-profit organizations, and donor-funded programs has made these kits accessible to low-income populations who may not otherwise afford testing services. In regions with high HIV burden, testing initiatives are often supported through bilateral partnerships, development grants, and collaborations with pharmaceutical companies to ensure continuous supply and education around test use. Educational campaigns emphasize the importance of regular testing, especially for sexually active individuals, which has led to greater public willingness to use rapid kits. Additionally, regulatory bodies are streamlining approval pathways for new kits to encourage innovation and market entry. Some governments are also implementing national procurement schemes and bulk purchasing agreements to ensure affordability and wide distribution. These policy-driven efforts are not just removing barriers to access but also strengthening infrastructure for follow-up care, treatment linkage, and monitoring. Together, they create a supportive ecosystem where rapid HIV testing is normalized and scaled across communities globally.

What Factors Are Driving the Continued Growth of the HIV Rapid Test Kits Market Worldwide?

The growth of the HIV rapid test kits market is being propelled by a blend of epidemiological, technological, social, and economic factors that collectively reflect the global need for accessible and reliable diagnostic tools. The persistent global prevalence of HIV, particularly in sub-Saharan Africa, parts of Asia, and marginalized communities in developed countries, underscores the ongoing need for wide-scale testing initiatives. Increased public awareness about HIV and sexually transmitted infections is motivating more individuals to seek regular testing, especially among younger populations and those with multiple partners. In parallel, the expansion of telemedicine and e-health platforms is facilitating the distribution and usage of self-test kits, further broadening market reach. The affordability and simplicity of rapid kits make them especially appealing in lower-income settings, where traditional laboratory services are either unavailable or financially inaccessible. Innovations in logistics and distribution channels, such as vending machines in public places and pharmacy pick-up models, are making testing kits more visible and attainable. Moreover, global emergencies like the COVID-19 pandemic have underscored the importance of decentralized and self-administered diagnostics, strengthening the appeal of rapid testing formats. Ongoing research and development investments by both private companies and public institutions are yielding products that cater to different user needs, regulatory environments, and regional disease profiles. With the dual push of social acceptance and health system integration, HIV rapid test kits are evolving from niche products into essential public health tools. Their growing role in early diagnosis, treatment linkage, and epidemic control ensures that demand will continue to rise, shaping a resilient and responsive market well into the future.

SCOPE OF STUDY:

The report analyzes the Human Immunodeficiency Virus (HIV) Rapid Test Kits market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (HIV Rapid Immunoassay Tests, HIV Rapid Molecular Diagnostic Tests); Distribution Channel (Offline Distribution Channel, Online Distribution Channel); End-Use (Diagnostic Centers End-Use, Hospitals & Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â